Progyny, Inc. (PGNY)
NASDAQ:PGNY
Want to see PGNY full AI Analyst Report?
PGNY Stock Chart & Stats
$18.12
$0.60(3.43%)
At close: 4:00 PM EST
$18.12
$0.60(3.43%)
Day’s Range― - ―
52-Week Range$16.10 - $28.75
Previous CloseN/A
Volume466.97K
Average Volume (3M)1.65M
Market Cap
$1.97B
Enterprise Value$1.90B
Total Cash (Recent Filing)$226.15M
Total Debt (Recent Filing)$27.28M
Price to Earnings (P/E)30.0
Beta0.73
Next Earnings
Jul 30, 2026EPS Estimate
0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.81
Shares Outstanding78,332,370
10 Day Avg. Volume1,660,018
30 Day Avg. Volume1,646,048
Financial Highlights & Ratios
PEG Ratio2.45
Price to Book (P/B)4.24
Price to Sales (P/S)1.70
P/FCF Ratio11.41
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue1.47
Enterprise Value/Gross Profit6.08
Enterprise Value/Ebitda17.54
Forecast
1Y Price Target
$29.38Price Target Upside62.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)1.28
Revenue Forecast (FY)$1.38B
Bulls Say, Bears Say
Bulls Say
Employer-focused, Sticky Benefits ModelProgyny’s specialized employer-sponsored benefits model creates recurring, contract-driven revenue and high switching costs. The curated provider network plus dedicated care advocates increases member stickiness and outcomes, supporting durable customer retention and long-term contract renewals across employers.
Re-accelerating Revenue MomentumA sustained re-acceleration in revenue indicates expanding adoption and stronger sales execution versus recent years. When combined with growth excluding a transition client, it signals underlying demand strength and improving organic growth that should support revenue visibility over the next several quarters.
Conservative Balance Sheet & Strong Cash FlowMinimal leverage and material operating and free cash flow provide financial flexibility to invest, fund buybacks, or weather cycles. This balance sheet strength reduces refinancing risk, supports capital allocation choices, and underpins long-term resilience of operations and strategic initiatives.
Bears Say
Operating Margin PressureA meaningful decline in operating margin reflects reinvestment and cost pressures that may persist as the company builds platform capabilities. If margin recovery lags revenue growth, profitability elasticity weakens, constraining free cash flow and long-term margin sustainability despite top-line gains.
Weaker Free-cash-flow MomentumDeclining FCF growth and deteriorating cash conversion reduce the company’s near-term ability to fund investments or return capital without drawing on reserves. Sustained weaker cash conversion would force tighter trade-offs between growth spending, buybacks, or balance sheet replenishment.
Comparability And Client Concentration RiskDependence on sizeable clients and transitions creates lumpy revenue and headline volatility. Large-client losses or timing shifts in renewals can materially affect reported growth and utilization assumptions, raising structural execution and retention risk for multi-year revenue stability.
Progyny News
PGNY FAQ
What was Progyny, Inc.’s price range in the past 12 months?
Progyny, Inc. lowest stock price was $16.10 and its highest was $28.75 in the past 12 months.
What is Progyny, Inc.’s market cap?
Progyny, Inc.’s market cap is $1.97B.
When is Progyny, Inc.’s upcoming earnings report date?
Progyny, Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 57 days.
How were Progyny, Inc.’s earnings last quarter?
Progyny, Inc. released its earnings results on May 07, 2026. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.256 by $0.034.
Is Progyny, Inc. overvalued?
According to Wall Street analysts Progyny, Inc.’s price is currently Undervalued.
Does Progyny, Inc. pay dividends?
Progyny, Inc. does not currently pay dividends.
What is Progyny, Inc.’s EPS estimate?
Progyny, Inc.’s EPS estimate is 0.33.
How many shares outstanding does Progyny, Inc. have?
Progyny, Inc. has 78,332,370 shares outstanding.
What happened to Progyny, Inc.’s price movement after its last earnings report?
Progyny, Inc. reported an EPS of $0.29 in its last earnings report, beating expectations of $0.256. Following the earnings report the stock price went up 23.8%.
Which hedge fund is a major shareholder of Progyny, Inc.?
Currently, no hedge funds are holding shares in PGNY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Progyny Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.38 (62.11% Upside)
$29.38 (62.11% Upside)
Blogger Sentiment
Bullish
PGNY Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 872.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $137.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 7.6%
Last 30 Days ▲ 7.6%
News Sentiment
Bullish
Bullish news 79%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.76%
12-Months-Change
Fundamentals
Return on Equity
13.34%
Trailing 12-Months
Asset Growth
-4.37%
Trailing 12-Months
Company Description
Progyny, Inc.
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
PGNY Company Deck
PGNY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized multiple operational and financial strengths: record Q1 revenue (at the high end of guidance), beats on net income/EPS/adjusted EBITDA, expanded gross margins, strong cash generation, completed a $200M buyback, and a de-risked renewal season with pipeline and early commitments pacing ahead of last year. Management raised full-year profitability guidance and maintained utilization and ART consumption assumptions. Challenges noted—administrative eligibility true-ups, ongoing investments (higher CapEx), comparability headwinds from a transition client, and conservative assumptions to guard against potential variability—are being actively managed and appear incremental rather than existential. Given the balance of robust financial results, validated clinical outcomes, and proactive mitigation of operational issues, the overall tone is constructive.View all PGNY earnings summariesPGNY Stock 12 Month Forecast
Average Price Target
$29.38
▲(62.11% Upside)
Technical Analysis
Ownership Overview
2.84% Insiders
34.20% Mutual Funds
21.39% Other Institutional Investors
10.83% Public Companies and
Individual Investors